Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?

Vertex Pharmaceuticals Incorporated (VRTX) will report fourth-quarter and full-year 2024 earnings result on Feb. 10, after market close. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $2.77 billion and$3.99 per share, respectively. Earnings estimates for Vertex for 2025 have declined from $18.25 to$18.19 per share over the past 30 days.See the Zacks Earnings Calendar to stay ahead of market-making news.Image Source: Zacks Investment ResearchVRTX's Earnings Surprise ...